ZINK-TRINATRIUM-PENTETAT (Zn-DTPA)
Ready for Emergency?
Are you not a health professional or industry expert? Find more information here
Active Pharmaceutical Ingredient: Trisodium zinc pentetate (Zn-DTPA)
Brand Name: Zink-Trinatrium-pentetat (Zn-DTPA)
ATC-Code : V03AB47 Pentetic acid
Pharmaceutical form: Solution for injection for intravenous use
Indication:
- Long-term treatment for decorporation of transuranium heavy metal nuclides (americium, plutonium, curium, californium, and berkelium).
Mechanism of Action:
Apart from releasing the zinc ion instead of the calcium ion, the mechanism of action of Zn-DTPA is identical to that of Ca-DTPA.
After initiation of treatment of an acute poisoning with the more potent Ca-DTPA the long-term treatment should then be continued with the less toxic Zn-DTPA.
Recommended Dosage:
The dosage of Zink-Trinatrium-pentetat (Zn-DTPA) is adjusted according to type and severity of intoxication.
In average the following regimen for adults applies:
- 1055 mg daily for 5 days
- followed by 2–3 times 1055 mg per week
- Pls. refer to the SmPC
Zn-DTPA is also suitable for children in a dosage of 25 - 50 mg per kg body weight and day.
WARNINGS and PRECAUTIONS
The treatment of intoxications with Zink-Trinatrium-pentetat (Zn-DTPA) does not preclude other forms
of therapies of intoxications, for instance gastrolavage, dialysis, plasma exchange, surgical resection
of depots etc.
At repeated administrations of Zn-DTPA with too short regeneration intervals between the single ones,
the following symptoms may occur: Delayed fever reaction, nausea, vomiting, diarrhoea, shiver,
headaches, pruritus, muscular cramps.
Possible side effects
Thrombophlebitic reactions have been described at a rapid intravenous injection.
Contact us directly for more information!